头孢他啶-阿维巴坦治疗碳青霉烯耐药革兰氏阴性杆菌感染引起的重症肺炎患者的疗效及安全性分析<sup>*</sup>

doi:10.3969/j.issn.1671-7171.2026.01.002

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1193 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the efficacy and safety of ceftazidime-avibactam(CAZ-AVI) in the treatment of patients with severe pneumonia caused by carbapenem-resistant organism(CRO) infection. 【Methods】 A total of 71 patients with severe pneumonia caused by CRO infection admitted to our hospital from September 2019 to October 2020 were selected. Among them, 38 cases received CAZ-AVI-based combined therapy and were included in the CAZ-AVI group, and 33 cases received anti-CRO combined therapy except CAZ-AVI and were included in the control group. The white blood cell count(WBC), C-reactive protein(CRP), procalcitonin(PCT), interleukin-6(IL-6), Acute Physiology and Chronic Health Evaluation Ⅱ(APACHE Ⅱ) score, Sequential Organ Failure Assessment(SOFA) score before and after anti-infective treatment, duration of antibiotic use, mechanical ventilation time, length of stay in respiratory intensive care unit(RICU), RICU survival rate, 28-day survival rate and incidence of adverse reactions were compared between the two groups. 【Results】 After treatment, the levels of WBC, CRP, PCT and IL-6 in the CAZ-AVI group were significantly lower than those in the control group(P<0.05), and the APACHE Ⅱ score and SOFA score were significantly lower than those in the control group(P<0.05). The incidence of hyperpigmentation in the CAZ-AVI group was significantly lower than that in the control group(P<0.05). The duration of anti-infective treatment and mechanical ventilation time in the CAZ-AVI group were shorter than those in the control group(P<0.05), and the RICU survival rate and 28-day survival rate were higher than those in the control group(P<0.05). 【Conclusion】 For patients with severe pneumonia caused by CRO infection, CAZ-AVI-based combined therapy is more effective and safer, with higher survival rate, which has a good clinical application prospect.

Key words： Pneumonia Ceftazidime Beta-Lactamase Inhibitors Drug Resistance, Bacterial Treatment Outcome

Received: 23 July 2025

PACS:

R563.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Ruixia
	ZHANG Xiaoshan
	LI Shuangfeng

Cite this article:

ZHANG Ruixia,ZHANG Xiaoshan,LI Shuangfeng. Efficacy and Safety Analysis of Ceftazidime-Avibactam in the Treatment of Severe Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacilli Infection[J]. JOURNAL OF CLINICAL RESEARCH, 2026, 43(1): 5-8.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2026.01.002 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2026/V43/I1/5

[1] RUSSELL F M, REYBURN R, CHAN J, et al.Impact of the change in WHO's severe pneumonia case definition on hospitalized pncumonia cpidcmiology:casc studics rrom six countrics[J].Bull World Health Organ,2019, 97(6): 386-393.
[2] LISA V D L, HILL A M, PATMAN S. Efficacy of a respiratory physiotherapy intervention for intubated and mechanically ventilated adults with community acquired pneumonia[J].JBI Database System Rev Implement Rep,2017,15(6):1508-1511.
[3] 翁志骏,陈险峰,胡海清.ICU呼吸道标本病原菌分布及耐药性分析[J].实用检验医师杂志,2018,10(4):234-236.
[4] TEMKIN E, TORRE-CISNEROS J, BEOVIC B, et al. Ceftazidime-Avibactam as salvage therapy for infections caused by carbapenem-resistant organisms [J].Antimicrob Agents Chemother,2017, 61(2): e01964.
[5] 中华医学会呼吸病学分会. 中国成人社区获得性肺炎诊断和治疗指南(2016年版)[J].中华结核和呼吸杂志,2016,39:253-279.
[6] ZHANG W X, GUO Y, LI J Y, et al. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against carbapenemaseproducing Klebsiella pneumoniae[J].Antimicrob Resist Infect Control,2018, 7:142.
[7] SADER H S, CASTANHEIRA M, FLAMM R K, et al. Ceftazidime/avibactam tested against gram-negative bacteria from intensive care unit(ICU) and non-ICU patients, including those with ventilator-associated pneumonia[J].Int J Antimicrob Agents,2015, 46(1): 53-59.
[8] WU X M, ZHU Y F, CHEN Q Y, et al. Tigecycline therapy for nosocomial pneumonia due to carbapenem-resistant gram-negative bacteria in critically ill patients who received inappropriate initial antibiotic treatment: a retrospective case study[J].Biomed Res Int,2016, 2016: 1-7.
[9] LIANG Q Q, HUANG M, XU Z J. Early use of polymyxin B reduces the mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection[J].Braz J Infect Dis,2019, 23(1): 60-65.
[10] SOBIESZCZYK M E. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections[J].J Antimicrob Chemother,2004, 54(2): 566-569.
[11] TSOLAKI V, MANTZARLIS K, MPAKALIS A, et al. Ceftazidime-avibactam to treat life-threatening Infections by carbapenem-resistant pathogens in critically ill mechanically ventilated patients [J].Antimicrob Agents Chemother,2020, 64(3): e02320.
[12] FAN L C ,XU J F .Advantages and drawbacks of long-term macrolide use in the treatment of non-cystic fibrosis bronchiectasis[J].J Thorac Dis,2014,6(7):867-871.
[13] KUMAR A, ROBERTS D, WOOD K E, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock [J].Crit Care Med,2006, 34(6): 1589-1596.
[14] FENG M C, SUN T T, ZHAO Y X, et al. Detection of serum interleukin-6/10/18 levels in sepsis and its clinical significance [J].J Clin Lab Anal,2016, 30(6): 1037-1043.
[15] CHEN W H, SUN L X, GUO L J, et al. Clinical outcomes of ceftazidime-avibactam in lung transplant recipients with infections caused by extensively drug-resistant gram-negative bacilli [J].Ann Transl Med,2020, 8(3):39.
[16] MATTOS K P H, CINTRA M L, GOUVÊA I R, et al. Skin hyperpigmentation following intravenous polymyxin B treatment associated with melanocyte activation and inflammatory process[J].J Clin Pharm Ther,2017, 42(5): 573-578.